New Tysabri data released
15 April 2008
Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc have announced new data on the global utilization, safety and overall patient exposure of TYSABRI® ((natalizumab); humanized by MRCT). "These data suggest that neurologists and patients are increasingly choosing TYSABRI for the treatment of their disease."
Click here to read the full article on PharmaLive.
